A study by Curtis et al., evaluating ILD incidence and exacerbation among RA patients treated with MOAs (abatacept, rituximab, and tocilizumab) compared with anti-TNFα agents, showed no significant differences regarding the risk of ILD and its related complications. The gene discussed is TNF; the disease is rheumatoid arthritis.